Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 973

1.

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study of the MYSEC group.

Mora B, Guglielmelli P, Rumi E, Maffioli M, Barraco D, Rambaldi A, Caramella M, Komrokji RS, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Albano F, Benevolo G, Cavalloni C, Uccella S, Accetta R, Siracusa C, Agnoli S, Merli M, Barbui T, Bertù L, Cazzola M, Vannucchi AM, Passamonti F.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25644. [Epub ahead of print] No abstract available.

PMID:
31588594
2.

Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.

Rogliani P, Matera MG, Ritondo BL, De Guido I, Puxeddu E, Cazzola M, Calzetta L.

Pulm Pharmacol Ther. 2019 Sep 11;59:101841. doi: 10.1016/j.pupt.2019.101841. [Epub ahead of print]

PMID:
31520718
3.

Pharmacological treatment and current controversies in COPD.

Cazzola M, Rogliani P, Stolz D, Matera MG.

F1000Res. 2019 Aug 29;8. pii: F1000 Faculty Rev-1533. doi: 10.12688/f1000research.19811.1. eCollection 2019. Review.

4.

Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.

Cazzola M, Calzetta L, Rogliani P, Matera MG.

Expert Opin Investig Drugs. 2019 Oct;28(10):827-833. doi: 10.1080/13543784.2019.1661990. Epub 2019 Sep 1.

PMID:
31474120
5.

Ultra-LABAs for the treatment of asthma.

Cazzola M, Rogliani P, Matera MG.

Respir Med. 2019 Sep;156:47-52. doi: 10.1016/j.rmed.2019.08.005. Epub 2019 Aug 12. Review.

PMID:
31425937
6.

A potential role of triple therapy for asthma patients.

Cazzola M, Puxeddu E, Matera MG, Rogliani P.

Expert Rev Respir Med. 2019 Nov;13(11):1079-1085. doi: 10.1080/17476348.2019.1657408. Epub 2019 Sep 1.

PMID:
31422716
7.

Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis.

Rogliani P, Calzetta L, Ora J, Cazzola M, Matera MG.

Multidiscip Respir Med. 2019 Aug 3;14:25. doi: 10.1186/s40248-019-0189-0. eCollection 2019.

8.

Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers.

Cazzola M, Puxeddu E, Ora J, Rogliani P.

Mol Diagn Ther. 2019 Oct;23(5):603-614. doi: 10.1007/s40291-019-00413-1. Review.

PMID:
31363933
9.

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment.

Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M.

Pulm Pharmacol Ther. 2019 Oct;58:101828. doi: 10.1016/j.pupt.2019.101828. Epub 2019 Jul 23. Review.

PMID:
31349002
10.

Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.

Rogliani P, Matera MG, Calzetta L, Hanania NA, Page C, Rossi I, Andreadi A, Galli A, Coppola A, Cazzola M, Lauro D.

Respir Med. 2019 Jul - Aug;154:86-92. doi: 10.1016/j.rmed.2019.06.015. Epub 2019 Jun 18.

PMID:
31228775
11.

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.

Mora B, Rumi E, Guglielmelli P, Barraco D, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Pietra D, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Giorgino T, Passamonti F.

Cancer Med. 2019 Aug;8(9):4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7.

12.

Defining Maximum Ecological Potential for heavily modified lowland streams of Northern Italy.

Erba S, Terranova L, Cazzola M, Cason M, Buffagni A.

Sci Total Environ. 2019 Sep 20;684:196-206. doi: 10.1016/j.scitotenv.2019.05.348. Epub 2019 May 24.

PMID:
31153067
13.

Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics.

Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG.

Trends Pharmacol Sci. 2019 Jul;40(7):452-463. doi: 10.1016/j.tips.2019.04.015. Epub 2019 May 27. Review.

PMID:
31147200
14.

Cytocompatible and Anti-bacterial Adhesion Nanotextured Titanium Oxide Layer on Titanium Surfaces for Dental and Orthopedic Implants.

Ferraris S, Cochis A, Cazzola M, Tortello M, Scalia A, Spriano S, Rimondini L.

Front Bioeng Biotechnol. 2019 May 9;7:103. doi: 10.3389/fbioe.2019.00103. eCollection 2019.

15.

Monoclonal antibodies for severe asthma: Pharmacokinetic profiles.

Matera MG, Calzetta L, Rogliani P, Cazzola M.

Respir Med. 2019 Jul;153:3-13. doi: 10.1016/j.rmed.2019.05.005. Epub 2019 May 13. Review.

PMID:
31136930
16.

Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.

Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L.

Respir Res. 2019 May 27;20(1):104. doi: 10.1186/s12931-019-1078-y.

17.

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation.

Rotunno G, Mannarelli C, Brogi G, Pacilli A, Gesullo F, Mannelli F, Fiaccabrino S, Sordi B, Paoli C, Marone I, Rumi E, Manfredini R, Barosi G, Cazzola M, Vannucchi AM, Guglielmelli P.

Blood. 2019 Jun 27;133(26):2802-2808. doi: 10.1182/blood.2018879536. Epub 2019 May 10. No abstract available.

PMID:
31076447
18.

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.

Schischlik F, Jäger R, Rosebrock F, Hug E, Schuster M, Holly R, Fuchs E, Milosevic Feenstra JD, Bogner E, Gisslinger B, Schalling M, Rumi E, Pietra D, Fischer G, Faé I, Vulliard L, Menche J, Haferlach T, Meggendorfer M, Stengel A, Bock C, Cazzola M, Gisslinger H, Kralovics R.

Blood. 2019 Jul 11;134(2):199-210. doi: 10.1182/blood.2019000519. Epub 2019 May 7.

19.

Response.

Calzetta L, Cazzola M, Matera MG, Rogliani P.

Chest. 2019 May;155(5):1079-1080. doi: 10.1016/j.chest.2019.01.028. No abstract available.

PMID:
31060694
20.

Bronchodilators in subjects with asthma-related comorbidities.

Cazzola M, Rogliani P, Calzetta L, Matera MG.

Respir Med. 2019 May;151:43-48. doi: 10.1016/j.rmed.2019.04.001. Epub 2019 Apr 3. Review.

PMID:
31047116
21.

Cardiovascular Disease in Chronic Respiratory Disorders and Beyond.

Rogliani P, Cazzola M, Calzetta L.

J Am Coll Cardiol. 2019 May 7;73(17):2178-2180. doi: 10.1016/j.jacc.2018.11.068. No abstract available.

PMID:
31047005
22.

Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms.

Rumi E, Zibellini S, Boveri E, Cavalloni C, Riboni R, Casetti IC, Ciboddo M, Trotti C, Favaron C, Pietra D, Candido C, Ferretti VV, Cazzola M, Arcaini L.

Am J Hematol. 2019 Jul;94(7):E185-E188. doi: 10.1002/ajh.25489. Epub 2019 May 1. No abstract available.

PMID:
30972817
23.

Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome.

Bono E, McLornan D, Travaglino E, Gandhi S, Gallì A, Khan AA, Kulasekararaj AG, Boveri E, Raj K, Elena C, Ireland RM, Bianchessi A, Jiang J, Todisco G, Ferretti VV, Cazzola M, Marsh JCW, Malcovati L, Mufti GJ.

Leukemia. 2019 Oct;33(10):2495-2505. doi: 10.1038/s41375-019-0457-1. Epub 2019 Apr 2.

PMID:
30940907
24.

Clonal monocytosis of clinical significance.

Cazzola M.

Blood. 2019 Mar 21;133(12):1271-1272. doi: 10.1182/blood-2019-01-896084. No abstract available.

PMID:
30898774
25.

Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways.

Calzetta L, Rogliani P, Page C, Rinaldi B, Cazzola M, Matera MG.

Pulm Pharmacol Ther. 2019 Jun;56:39-50. doi: 10.1016/j.pupt.2019.03.004. Epub 2019 Mar 12.

PMID:
30876907
26.

Introduction to a review series on transfusion medicine.

Cazzola M.

Blood. 2019 Apr 25;133(17):1793-1794. doi: 10.1182/blood-2019-01-888248. Epub 2019 Feb 26. No abstract available.

PMID:
30808640
27.

Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease.

Rogliani P, Calzetta L, Matera MG, di Daniele N, Girolami A, Cazzola M, Ora J.

Expert Opin Pharmacother. 2019 Apr;20(6):737-750. doi: 10.1080/14656566.2019.1570133. Epub 2019 Feb 1. Review.

PMID:
30707637
28.

Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.

Calzetta L, Cazzola M, Matera MG, Rogliani P.

Chest. 2019 Apr;155(4):758-770. doi: 10.1016/j.chest.2018.12.016. Epub 2019 Jan 17.

PMID:
30660781
29.

Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.

Cazzola M, Page C, Calzetta L, Matera MG.

Pharm Pat Anal. 2018 Nov;7(6):249-257. doi: 10.4155/ppa-2018-0030. Epub 2019 Jan 18.

PMID:
30657422
30.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

31.

Introduction to a review series on iron metabolism and its disorders.

Coates TD, Cazzola M.

Blood. 2019 Jan 3;133(1):1-2. doi: 10.1182/blood-2018-10-876466. Epub 2018 Nov 14. No abstract available.

PMID:
30429162
32.

Varenicline for long term smoking cessation in patients with COPD.

Hernández Zenteno RJ, Lara DF, Venegas AR, Sansores RH, Pineda JR, Trujillo FF, Pérez Padilla JR, Matera MG, Cazzola M.

Pulm Pharmacol Ther. 2018 Dec;53:116-120. doi: 10.1016/j.pupt.2018.11.001. Epub 2018 Nov 3.

PMID:
30399395
33.

An inhaled "bifunctional" dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD.

Cazzola M, Page C.

Eur Respir J. 2018 Nov 1;52(5). pii: 1801675. doi: 10.1183/13993003.01675-2018. Print 2018 Nov. No abstract available.

PMID:
30385603
34.

Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents.

Matera MG, Rogliani P, Ora J, Cazzola M.

Expert Opin Pharmacother. 2018 Dec;19(18):2043-2053. doi: 10.1080/14656566.2018.1534957. Epub 2018 Oct 25. Review.

PMID:
30359143
35.

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.

Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E, Pelaia G, Rossi A, Scichilone N, Di Marco F.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 4;13:3115-3130. doi: 10.2147/COPD.S170606. eCollection 2018.

36.

Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis.

Cazzola M, Rogliani P, Calzetta L, Matera MG.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801586. doi: 10.1183/13993003.01586-2018. Print 2018 Dec. Review.

PMID:
30309975
37.

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F.

Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x. No abstract available.

38.

Rebuttal From Drs Cazzola and Matera.

Cazzola M, Matera MG.

Chest. 2018 Oct;154(4):751-752. doi: 10.1016/j.chest.2018.06.023. No abstract available.

PMID:
30290927
39.

POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes.

Cazzola M, Matera MG.

Chest. 2018 Oct;154(4):746-748. doi: 10.1016/j.chest.2018.06.022. No abstract available.

PMID:
30290925
40.

Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease.

Matera MG, Rinaldi B, Page C, Rogliani P, Cazzola M.

Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1101-1111. doi: 10.1080/17425255.2018.1530215. Epub 2018 Oct 9. Review.

PMID:
30261755
41.

Infection perturbs Bach2- and Bach1-dependent erythroid lineage 'choice' to cause anemia.

Kato H, Itoh-Nakadai A, Matsumoto M, Ishii Y, Watanabe-Matsui M, Ikeda M, Ebina-Shibuya R, Sato Y, Kobayashi M, Nishizawa H, Suzuki K, Muto A, Fujiwara T, Nannya Y, Malcovati L, Cazzola M, Ogawa S, Harigae H, Igarashi K.

Nat Immunol. 2018 Oct;19(10):1059-1070. doi: 10.1038/s41590-018-0202-3. Epub 2018 Sep 24.

PMID:
30250186
42.

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology.

D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 7;13:2805-2819. doi: 10.2147/COPD.S113306. eCollection 2018. Review.

43.

Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2).

Calzetta L, Hanania NA, Dini FL, Goldstein MF, Fairweather WR, Howard WW, Cazzola M.

Pulm Pharmacol Ther. 2018 Dec;53:20-26. doi: 10.1016/j.pupt.2018.09.007. Epub 2018 Sep 13.

44.

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS.

Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Santini V, Lübbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Leuk Res. 2018 Oct;73:51-57. doi: 10.1016/j.leukres.2018.08.022. Epub 2018 Sep 6.

45.

Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia.

Shiozawa Y, Malcovati L, Gallì A, Sato-Otsubo A, Kataoka K, Sato Y, Watatani Y, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Makishima H, Shiraishi Y, Chiba K, Hellström-Lindberg E, Miyano S, Ogawa S, Cazzola M.

Nat Commun. 2018 Sep 7;9(1):3649. doi: 10.1038/s41467-018-06063-x.

46.

Benefits and risks of JAK inhibition.

Arcaini L, Cazzola M.

Blood. 2018 Aug 16;132(7):675-676. doi: 10.1182/blood-2018-07-858720. No abstract available.

PMID:
30115632
47.

Green Tea Polyphenols Coupled with a Bioactive Titanium Alloy Surface: In Vitro Characterization of Osteoinductive Behavior through a KUSA A1 Cell Study.

Cazzola M, Ferraris S, Boschetto F, Rondinella A, Marin E, Zhu W, Pezzotti G, Vernè E, Spriano S.

Int J Mol Sci. 2018 Aug 1;19(8). pii: E2255. doi: 10.3390/ijms19082255.

48.

Emerging antibacterial and antiviral drugs for treating respiratory tract infections.

Mantero M, Rogliani P, Cazzola M, Blasi F, Di Pasquale M.

Expert Opin Emerg Drugs. 2018 Sep;23(3):185-199. doi: 10.1080/14728214.2018.1504020. Epub 2018 Jul 30. Review.

PMID:
30032674
49.

Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.

Zappasodi P, Marbello L, Borlenghi E, Fumagalli M, Bernardi M, Fracchiolla N, Mancini V, Da Vià M, Ravano E, Cerqui E, Ferretti VV, Rocca B, Calvello C, Cazzola M, Castagnola C, Rossi G.

Ann Hematol. 2018 Nov;97(11):2107-2115. doi: 10.1007/s00277-018-3424-4. Epub 2018 Jul 15.

PMID:
30009341
50.

Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera.

Bertozzi I, Rumi E, Cavalloni C, Cazzola M, Fabris F, Randi ML.

Am J Hematol. 2018 Sep;93(9):E234-E235. doi: 10.1002/ajh.25210. Epub 2018 Aug 31. No abstract available.

Supplemental Content

Loading ...
Support Center